• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SIMVASTATIN Drug Record

  • Summary
  • Interactions
  • Claims
  • SIMVASTATIN chembl:CHEMBL1064 Approved

    Alternate Names:

    RANZOLONT
    ZOCOR
    ZOCOR HEART-PRO
    SIMVASTATIN HYDROXY ACID
    SIMVADOR
    SIMVASTATIN
    C10AA01
    MK-733
    MK-0733
    SYNVINOLIN
    LACERSA
    FLOLIPID
    (1S,3R,7S,8S,8AR)-8-{2-[(2R,4R)-4-HYDROXY-6-OXOOXAN-2-YL]ETHYL}-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2,2-DIMETHYLBUTANOATE
    MODUTROL
    LIPOVAS
    SINVASCOR
    CHOLESTAT
    NOR-VASTINA
    SIMVASTATIN LACTONE
    2,2-DIMETHYLBUTYRIC ACID, 8-ESTER WITH (4R,6R)-6-(2-((1S,2S,6R,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-8-HYDROXY-2,6-DIMETHYL-1-NAPHTHYL)ETHYL)TETRAHYDRO-4-HYDROXY-2H-PYRAN-2-ONE
    SIMCOR
    SIMVASTATINUM
    SINVACOR
    LIPINORM
    ZOCORD
    EUCOR
    KOLESTEVAN
    (+)-SIMVASTATIN
    VALEMIA
    ZOCOR®
    SIMVASTATINE
    LIPEX
    SIVASTIN
    LIPONORM
    SIMVASTATINA
    RECHOL
    DENAN
    SIMOVIL
    SIV691
    VELOSTATIN
    SIMVOTIN
    PEPSTATIN
    LODALES
    rxcui:36567
    drugbank:00641
    chemidplus:79902-63-9
    chembl:CHEMBL1064
    pubchem.compound:54454

    Drug Info:

    Drug Indications antidyslipidaemic agent
    Drug Indications anticholesterolaemic agent
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypertensive agent
    Drug Class anticholesteremic agents
    Year of Approval 1991
    (4 More Sources)

    Publications:

    Hubacek JA et al., 2009, Impact of apolipoprotein A5 variants on statin treatment efficacy., Pharmacogenomics
    Tsamandouras N et al., 2014, Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach., Clin Pharmacol Ther
    de Keyser CE et al., 2013, Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study., Pharmacogenomics
    Hu M et al., 2013, Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia., Pharmacogenomics
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Huang et al., 2006, Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients., Eur. J. Clin. Invest.
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
    Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation
    Polisecki E et al., 2008, Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER., Atherosclerosis
    Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
    Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
    Chasman DI et al., 2004, Pharmacogenetic study of statin therapy and cholesterol reduction., JAMA
    Pappu et al., 2003, Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia., J. Lab. Clin. Med.
    Kocarek et al., 2002, Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes., Drug Metab. Dispos.
    Stoebner et al., 2003, [Simvastatin-induced lichen planus pemphigoides]., Ann Dermatol Venereol
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Liu et al., 2003, Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection., J Pharm Biomed Anal
    Cenedella et al., 2003, Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats., J. Lipid Res.
    Carbonell et al., 2005, Binding thermodynamics of statins to HMG-CoA reductase., Biochemistry
    Fiegenbaum M et al., 2005, Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes., Pharmacogenomics J
    Stogowska-Nikiciuk et al., 2008, [The influence of simvastatin on hsCRP and some paramneters of hemostasis in patients with ischemic heart disease]., Prz. Lek.
    Riessen et al., 1999, Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells., Basic Res. Cardiol.
    Ruaño G et al., 2007, Physiogenomic association of statin-related myalgia to serotonin receptors., Muscle Nerve
    Luzum JA et al., 2015, Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations., J Cardiovasc Pharmacol
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Zuccaro P et al., 2007, Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin., Pharmacol Res
    Kim KA et al., 2007, Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects., J Clin Pharmacol
    Fiegenbaum et al., 2005, The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment., Clin. Pharmacol. Ther.
    Kivistö KT et al., 2004, Lipid-lowering response to statins is affected by CYP3A5 polymorphism., Pharmacogenetics
    Shin MJ et al., 2005, A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients., Clin Chim Acta
    Iwuchukwu OF et al., 2014, Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting., Pharmacogenomics
    Sai K et al., 2016, A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients., Drug Metab Pharmacokinet
    Hubacek JA et al., 2015, Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population., Eur J Intern Med
    Hsieh et al., 2008, Simvastatin-induced heme oxygenase-1 increases apoptosis of Neuro 2A cells in response to glucose deprivation., Toxicol. Sci.
    Vanderlocht et al., 2006, Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls., J. Neuroimmunol.
    Chiou et al., 2006, Kinetics and mechanisms of cholesterol esterase inhibition by cardiovascular drugs in vitro., Indian J. Biochem. Biophys.
    Gerdes LU et al., 2000, The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study., Circulation
    Andersson ML et al., 2012, A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele., Pharmacogenomics
    Kendra KL et al., 2015, A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors., Mol Cancer Ther
    Hernández-Romero et al., 2008, Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide., J. Neurochem.
    Ruiz-Iruela C et al., 2018, KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment., PLoS One
    Hopewell JC et al., 2011, No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study., J Am Coll Cardiol
    Han et al., 2005, HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo., Circulation
    Murphy et al., 2008, Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients., Am. J. Physiol. Lung Cell Mol. Physiol.
    Kumano et al., 2000, HMG-CoA reductase inhibitor induces a transient activation of high affinity nerve growth factor receptor, trk, and morphological differentiation with fatal outcome in PC12 cells., Brain Res.
    Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.
    Becker ML et al., 2009, Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males., Pharmacogenomics
    Becker ML et al., 2010, Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy., Pharmacoepidemiol Drug Saf
    Sun YM et al., 2009, The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease., Eur J Clin Pharmacol
    Takahashi-Yasuno A et al., 2003, Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men., Diabetes Res Clin Pract
    Anagnostopoulou K et al., 2007, Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects., Expert Opin Pharmacother
    Mohrschladt MF et al., 2005, TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia., Eur J Hum Genet
    Lee et al., 2004, Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection., Circulation
    Voora D et al., 2008, Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response., Circ Cardiovasc Genet
    Medina MW et al., 2012, RHOA is a modulator of the cholesterol-lowering effects of statin., PLoS Genet
    Undas A et al., 2009, Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease., Atherosclerosis
    Tirkkonen et al., 2008, Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study., Drug Saf
    Cheung et al., 2001, Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin., Biochim. Biophys. Acta
    Nagila A et al., 2009, Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status., Pharmacol Rep
    Fu R et al., 2008, Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease., Clin Exp Pharmacol Physiol
    Himbergen TM et al., 2005, The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia., J Intern Med
    Keskitalo JE et al., 2009, Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin., Pharmacogenomics
    Becker ML et al., 2013, Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy., Pharmacogenomics J
  • SIMVASTATIN   F3

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19027114


    Sources:
    PharmGKB

  • SIMVASTATIN   HMGCR

    Interaction Score: 1.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name HL 007, simvastatin + amlodipine
    Novel drug target Established target
    Trial Name MK-0542B, extended release niacin + laropiprant +simvastatin

    PMIDs:
    16680159 18815589 18332269 18261733 17563401 16103896 15199031 12677170 12433810 12671581 11752352 12852453 12518039 16128575


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • SIMVASTATIN   PLTP

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11566255


    Sources:
    NCI

  • SIMVASTATIN   ICMT

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SIMVASTATIN   GATM

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMVASTATIN   SCAP

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16158080


    Sources:
    PharmGKB

  • SIMVASTATIN   LEPR

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18854995 14625131


    Sources:
    PharmGKB

  • SIMVASTATIN   KIF6

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30304062 21458191


    Sources:
    PharmGKB

  • SIMVASTATIN   RYR2

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27839692 25753936


    Sources:
    PharmGKB

  • SIMVASTATIN   PON1

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19904013 18430057 16238680


    Sources:
    PharmGKB

  • SIMVASTATIN   CYBA

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15936011


    Sources:
    PharmGKB

  • SIMVASTATIN   RHOA

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23166513


    Sources:
    PharmGKB

  • SIMVASTATIN   CEL

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16955753


    Sources:
    NCI

  • SIMVASTATIN   APOA5

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19530961


    Sources:
    PharmGKB

  • SIMVASTATIN   THBD

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18663903


    Sources:
    NCI

  • SIMVASTATIN   ABCA1

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20031551


    Sources:
    PharmGKB

  • SIMVASTATIN   LIPC

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896


    Sources:
    PharmGKB

  • SIMVASTATIN   TPM3

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10720627


    Sources:
    NCI

  • SIMVASTATIN   THBS1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10543307


    Sources:
    NCI

  • SIMVASTATIN   CETP

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17931083 15856070


    Sources:
    PharmGKB

  • SIMVASTATIN   CCR2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15781755


    Sources:
    NCI

  • SIMVASTATIN   LIF

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16797728


    Sources:
    NCI

  • SIMVASTATIN   HTR3B

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17600820


    Sources:
    PharmGKB

  • SIMVASTATIN   IL17A

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18203812


    Sources:
    NCI

  • SIMVASTATIN   APOE

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10736278


    Sources:
    PharmGKB

  • SIMVASTATIN   UGT1A9

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25493567


    Sources:
    PharmGKB

  • SIMVASTATIN   SLCO2B1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24598718


    Sources:
    PharmGKB

  • SIMVASTATIN   CYP3A5

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26164721 24598718 23252946 18695978 17289397 17192506 16321621 15284534


    Sources:
    NCI PharmGKB

  • SIMVASTATIN   HTR7

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17600820


    Sources:
    PharmGKB

  • SIMVASTATIN   MMP2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16436088


    Sources:
    NCI

  • SIMVASTATIN   CYP2C8

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25504632


    Sources:
    PharmGKB

  • SIMVASTATIN   UGT1A3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMVASTATIN   PPARA

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24598718 23930676 23252946


    Sources:
    PharmGKB

  • SIMVASTATIN   NR2E3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SIMVASTATIN   HLA-DRB1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27839692


    Sources:
    PharmGKB

  • SIMVASTATIN   SLCO1B3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMVASTATIN   ABCG2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24598718 19842935


    Sources:
    PharmGKB

  • SIMVASTATIN   UGT2B7

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMVASTATIN   ABCC2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22186618


    Sources:
    PharmGKB

  • SIMVASTATIN   BDNF

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18047562


    Sources:
    NCI

  • SIMVASTATIN   UGT1A1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMVASTATIN   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15616150 19891551 19802823 16321621


    Sources:
    NCI PharmGKB

  • SIMVASTATIN   PIK3CG

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15337692


    Sources:
    NCI

  • SIMVASTATIN   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22594507 17289397 22931300


    Sources:
    DTC PharmGKB

  • SIMVASTATIN   NR1I2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMVASTATIN   TARDBP

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SIMVASTATIN   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • SIMVASTATIN   PLK1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SIMVASTATIN   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18302447 22931300


    Sources:
    DTC NCI

  • SIMVASTATIN   CYP1A2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SIMVASTATIN   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SIMVASTATIN   IDH1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SIMVASTATIN   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17928392


    Sources:
    NCI

  • SIMVASTATIN   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: SIMVASTATIN

    • Version: 01-August-2011

    Alternate Names:
    SIMVASTATIN Primary Drug Name

    Drug Info:
    Year of Approval 1991
    Drug Class anticholesteremic agents

    Publications:

  • TdgClinicalTrial: SIMVASTATIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypertensive agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: SIMVASTATIN

    • Version: 14-September-2017

    Alternate Names:
    C29454 NCI drug code

    Drug Info:

    Publications:
    Han et al., 2005, HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo., Circulation
    Hsieh et al., 2008, Simvastatin-induced heme oxygenase-1 increases apoptosis of Neuro 2A cells in response to glucose deprivation., Toxicol. Sci.
    Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.

  • DTC: SIMVASTATIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1064 ChEMBL Drug ID

    Drug Info:

    Publications:
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: simvastatin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hubacek JA et al., 2009, Impact of apolipoprotein A5 variants on statin treatment efficacy., Pharmacogenomics
    de Keyser CE et al., 2013, Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study., Pharmacogenomics
    Tsamandouras N et al., 2014, Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach., Clin Pharmacol Ther

  • TTD: Simvastatin

    • Version: 2020.06.01

    Alternate Names:
    D0H0ND TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1064

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1064

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21